Gena Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Gena Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth and di…

2004-05-11 Kolkata, West Bengal Under Liquidation Unlisted Active Non-Compliant
Share
GP Gena Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Gena Pharmaceuticals Limited — 360° Intelligence Report

Generated from MCA filings & public records
29/100
Trust Score
Caution Indicated

Gena Pharmaceuticals Limited is assessed as Caution Indicated with a Trust Score of 29/100. Gena Pharmaceuticals Limited is a public limited indian non-government company incorporated in 2004, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 24 Jul 2026 from the latest processed filings. Gena Pharmaceuticals Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Caution
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreCaution Indicated
29/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
5/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
20/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.

Charges position: 3 open (32.29 cr) · 1 satisfied (11.54 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Edelweiss Asset Reconstruction Company Limited2 48.0 cr
United Bank Of India1 48.0 cr
Andhra Bank1 48.0 cr
Compliance Score: 5/100 Caution Indicated
  • Company status is "Under Liquidation" - not Active.
  • Marked ACTIVE non-compliant (INC-22A).
  • Last balance sheet is for Mar 2020 - filings overdue.
  • Flagged by authority: BANKS, NCLT.
  • Litigation present in 4 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (4)
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
SURESH KUMAR SHARMA 01234567 Director 01/04/2018 6 yrs Approved
ARABIND KUMAR MISHRA 01234567 Director 01/04/2018 6 yrs Approved
VIJAYKUMAR KANORIA 01234567 Director 01/04/2018 6 yrs Approved
ABHISHEK KUMAR SHUKLA 01234567 Director 01/04/2018 6 yrs Approved
SANTOSH KUMAR SHARMA 01234567 Director 01/04/2018 6 yrs Approved
RINTU BHATTACHARJEE 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • ARABIND KUMAR MISHRA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2018)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2019 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 20
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
Statutory filings appear overdue.
Adverse company status: Under Liquidation.
Compliance score is weak (5/100).
3 open charge(s) registered - assets are encumbered.
4 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence17/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment21/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 32.29 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view27/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
16 Dec 2022
Director appointed
SURESH KUMAR SHARMA (Additional Director)
Director appointed
SANTOSH KUMAR SHARMA (Additional Director)
Director appointed
RINTU BHATTACHARJEE (Additional Director)
28 Dec 2020
Last AGM held
Annual general meeting
31 Mar 2020
Latest balance sheet
Filed with ROC
30 Sep 2019
Director ceased
VIJAYKUMAR KANORIA
04 Jun 2019
Director appointed
ABHISHEK KUMAR SHUKLA (Additional Director)
Director ceased
RAJ KAMAL KANORIA
06 Mar 2013
Director ceased
BHOLA NATH NANDI
23 May 2012
Director appointed
VIJAYKUMAR KANORIA (Director)
17 May 2012
Director ceased
GOVIND PRASAD KANORIA
Director ceased
NAROTTAM DAN
30 Sep 2011
Director appointed
ARABIND KUMAR MISHRA (Additional Director)
13 Feb 2009
Charge satisfied
United Bank Of India
04 Oct 2008
Charge created
Edelweiss Asset Reconstruction Company Limited - 12.66 cr
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
6 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2019 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kairali U85191DL2007PTC167500 New Delhi, Delhi, India
Anagha Chem Private Limited U24100GJ2011PTC068221 Dahej, Gujarat, India
Bhartiya Agrow Pharma Private Limited U24231UP1996PTC019954 Kanpur, Uttar Pradesh, India
Sai Siddhi Pharmachem Private Limited U24230GJ2013PTC077705 Rajpipla, Gujarat, India
Vd Natural Biochem & Fertilizer Private Limited U24120WB2008PTC127153 Kolkata, West Bengal, India
Shikhara Laboratories Private Limited U24100TG2018PTC128852 Hyderabad, Telangana, India
Rosa Herbalcare (India) Private Limited U24247RJ2013PTC043245 Bhiwadi, Rajasthan, India
Nattura Bio-Care Private Limited U24231TN1998PTC040864 Chennai-24, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Gena Pharmaceuticals Limited before audits and certifications: compliance score 5/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Gena Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 45/100, margin trends, ownership structure and peer set for Gena Pharmaceuticals Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 29/100, distress signals and MSME payment-delay disclosures - know whether Gena Pharmaceuticals Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Gena Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Gena Pharmaceuticals Limited an active company?

Gena Pharmaceuticals Limited has MCA status “Under Liquidation” with a compliance score of 5/100 (Caution Indicated).

Is Gena Pharmaceuticals Limited financially healthy?

Gena Pharmaceuticals Limited has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Gena Pharmaceuticals Limited?

Its overall Trust Score is 29/100 (Caution Indicated). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Gena Pharmaceuticals Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.

Does Gena Pharmaceuticals Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Gena Pharmaceuticals Limited up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 5/100 (Caution Indicated).

Is it risky to lend to Gena Pharmaceuticals Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.